Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gemigliptin (LC15-0444) 是一种选择性的,可逆的,竞争性的二肽基肽酶 4 (DPP-4) 抑制剂,对人重组 DPP-4 的 IC50=10.3 nM。Gemigliptin 具有很强的抗糖基化活性,能够用于晚期糖基化终产物相关的糖尿病并发症的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 242 | 现货 | ||
2 mg | ¥ 338 | 现货 | ||
5 mg | ¥ 565 | 现货 | ||
10 mg | ¥ 898 | 现货 | ||
25 mg | ¥ 1,650 | 现货 | ||
50 mg | ¥ 2,730 | 现货 | ||
100 mg | ¥ 3,970 | 现货 | ||
500 mg | ¥ 8,860 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 755 | 现货 |
产品描述 | Gemigliptin (LC15-0444) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor(KD : 7.25 nM.) |
靶点活性 | DPP4:7.25 nM(KD) |
体外活性 | Gemigliptin attenuated vascular calcification and osteogenic trans-differentiation in vascular smooth muscle cells via multiple steps including downregulation of PiT-1 expression and suppression of reactive oxygen species generation, phospho-PI3K/AKT, and the Wnt signaling pathway[1].Gemigliptin treatment attenuated phosphorylated nuclear factor-κB levels, which had been increased in the UUO kidney as well as in TGF-β-treated cultured renal cells[2]. |
细胞实验 | Using immunohistochemical and Western blot analysis, Quantitated components of the NLRP3 inflammasome in kidneys with and without gemigliptin treatment, and in vitro in human kidney tubular epithelial human renal proximal tubule cells (HK-2) cells, further analyzed the effect of gemigliptin on transforming growth factor-β (TGF-β)-stimulated production of profibrotic proteins[2]. |
别名 | 吉格列汀酒石酸盐, LC15-0444 |
分子量 | 489.36 |
分子式 | C18H19F8N5O2 |
CAS No. | 911637-19-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 122.5 mg/mL (250.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0435 mL | 10.2174 mL | 20.4349 mL | 51.0871 mL |
5 mM | 0.4087 mL | 2.0435 mL | 4.087 mL | 10.2174 mL | |
10 mM | 0.2043 mL | 1.0217 mL | 2.0435 mL | 5.1087 mL | |
20 mM | 0.1022 mL | 0.5109 mL | 1.0217 mL | 2.5544 mL | |
50 mM | 0.0409 mL | 0.2043 mL | 0.4087 mL | 1.0217 mL | |
100 mM | 0.0204 mL | 0.1022 mL | 0.2043 mL | 0.5109 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Gemigliptin 911637-19-9 Proteases/Proteasome Ubiquitination Proteasome DPP-4 Inhibitor DPP Dipeptidyl Peptidase 吉格列汀酒石酸盐 inhibit LC15-0444 inhibitor